Nipah medicine row: Action after receiving expert panel report, says Keralam Health Minister

The Kerala Health Ministry has been under intense scrutiny after a controversial medicine for Nipah virus treatment was promoted without clear scientific backing. Health Minister Muraleedharan addressed the legislative assembly, stating that the information presented earlier was based on reports from senior health officials and that the government will await the expert panel's final report before taking any further steps. He emphasized that the ministry respects the panel's independence and will not issue additional statements until the findings are formally submitted.

Nipah virus, a zoonotic disease with a high mortality rate, has periodically resurfaced in parts of South Asia, prompting urgent calls for effective therapeutic options. The disputed medicine, which had been distributed in limited quantities, sparked debate among virologists, clinicians and public health experts about its efficacy and safety. The expert panel, comprising epidemiologists, pharmacologists and representatives from the Indian Council of Medical Research, was tasked with reviewing clinical data, manufacturing standards and regulatory compliance. Their assessment will determine whether the drug can be approved for wider use or withdrawn from the market.

The outcome of the panel's review holds significant implications for Kerala's public health strategy and for other Indian states monitoring Nipah threats. If the medicine is validated, it could become a key component of emergency response plans; if not, the episode may lead to stricter oversight of drug approvals during health crises. Observers will watch for the panel's report, any subsequent policy directives from the health ministry, and potential legal actions related to the earlier distribution of the drug.